Skip to content

To Compare Efficacy and safety of Topical Dapsone 5% versus Topical Clindamycin 1% In Treatment of Mild to Moderate Acne Vulgaris

OUTCOME OF TOPICAL DAPSONE 5% VERSUS TOPICAL CLINDAMYCIN 1% IN TREATMENT OF MILD TO MODERATE ACNE VULGARIS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250124064503N1
Enrollment
132
Registered
2025-02-03
Start date
2025-02-03
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris. Acne vulgaris

Interventions

Intervention 1: Intervention group 1: Dapsone 5% Gel. Intervention 2: Intervention group 2: Clindamycin 1%.

Sponsors

Khawaja Muhammad Safdar Medical College/Allama Iqbal Memorial Teaching Hospital, Pakistan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Both Males and Females 18-60 Years of age Mild to Moderate Acne Vulgaris as per Global Acne Grading Score

Exclusion criteria

Exclusion criteria: Pregnant patients and Lactating mothers Patients do not take any oral antibiotics for 4 weeks and topical antibiotics for 2 weeks Patients have other facial conditions besides acne vulgaris (e.g.' ,rosacea) Patients taking Glucocorticoids, Phenytoin, Isoniazid and Lithium Patients with history of allergy with the study medication

Design outcomes

Primary

MeasureTime frame
The Primary Outcome will be the mean Global Acne Grading System Score in Dapsone 5% group and the Clindamycin 1% group at the end of 12 weeks treatment period. Timepoint: 12 weeks. Method of measurement: Global Acne Grading System Score.

Secondary

MeasureTime frame
Other Variables like Irritation, Burning Sensation, Pruritis, Erythema and oily skin after use of the Topical Drugs. Timepoint: 12 weeks. Method of measurement: Question will be asked regarding above mentioned side effects.

Countries

Pakistan

Contacts

Public ContactMuhammad Bilal Iftikhar

Khawaja Muhammad Safdar Medical College

bilaliftikhar28@gmail.com+92 48 3256011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026